.AstraZeneca has actually utilized artificial intelligence to design a distinct biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), wanting to differentiate the antibody-drug conjugate (ADC)
Read moreAN 2 halves census, stops stage 3 test after data let down
.AN2 Therapies is actually rethinking its company in action to lackluster midphase data, pledging to give up half its own workers and cease a period
Read moreALX’s waning CD47 response price sends out sell spiraling down
.ALX Oncology’s period 2 gastric cancer response price has actually damaged. After observing its CD47 blocker effortlessly beat control over the 1st fifty percent of
Read moreAC Immune observes ‘site’ prospective in Alzheimer’s drug information
.After much more than 20 years of work with neurodegenerative diseases, Swiss biotech hvac Invulnerable claims it can possess a video game changer on its
Read more